Combined therapy of BAT activation (treatment of β3AR agonist) and caloric restriction synergistically improve NASH in an animal model, although BAT activation alone does not reverse NASH despite alleviation of steatosis [34]. The gene discussed is ADRB3; the disease is metabolic dysfunction-associated steatohepatitis.